Bifogade filer
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
ExpreS2ion completed a rights issue of units during the third quarter of 2024. Within the scope of the rights issue, ExpreS2ion issued in total 32,221,672 warrants of series TO 10, of which 30,046,672 warrants of series TO 10 were issued as a result of the rights issue, and an additional 2,175,000 warrants of series TO 10 were issued to rights issue guarantors who chose to receive guarantee compensation in units.
Prior to recalculation of the warrants of series TO 10, one (1) warrant of series TO 10 gave the owner the right to subscribe for one (1) new share in the Company. Following the recalculation of the warrants, which is explained in more detail below, forty (40) warrants of series TO 10 gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 10 was defined as 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during 1-14 November 2024 (the “measurement period”), but not less than the share's quota value (SEK 4.444444) (previously SEK 0.111111) and not more than SEK 60.00 (previously SEK 1.50) per share after recalculation. During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 25.59, therefore the exercise price for the warrants of series TO 10 has been set to SEK 17.91. The exercise period for warrants of series TO 10 runs from 20 November 2024 up to and including 4 December 2024.
If all the warrants of series TO 10 are exercised, the Company will receive approximately SEK 14.4 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than on 4 December 2024 or sell the warrants no later than on 2 December 2024. Please observe that certain nominees might close their applications earlier than on 4 December 2024.
Full terms and conditions regarding the warrants of series TO 10 and information about the Company is available in the prospectus which was approved by the Swedish Financial Supervisory Authority (the "SFSA") and published by the Company on 5 June 2024. The prospectus is available on the Company's investor relations website investor.expres2ionbio.com, as well as the SFSA's website www.fi.se.
Recalculation of outstanding warrants of series TO 10
Due to the recent reverse share split in the Company, as resolved at the extraordinary general meeting on 21 October 2024, a recalculation has been made in accordance with the terms and conditions of the Company's warrants of series TO 10 regarding the subscription price and the number of shares that each warrant entitles to subscribe for. Other terms and conditions for the warrants of series TO 10 will remain unchanged. The total number of outstanding warrants have not changed as a result of the reverse share split and the recalculation.
After the recalculation, the subscription price per share when exercising warrants of series TO 10 shall correspond to 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the period from and including 1 November 2024 until and including 14 November 2024, however, not less than the share's quota value (SEK 4.444444) and not more than SEK 60.00 (previously SEK 1.50). The new number of shares that each warrant entitles to subscribe for amounts to 0.025 shares (previously one (1) share) after the recalculation. Subscription cannot be made by part of a share, which means that forty (40) warrants of series TO 10 will be required to subscribe for one (1) new share in the Company. Note that warrants of series TO 10 that are not sold by 2 December 2024 or exercised by 4 December 2024 expire without value.
Summarised terms for the warrants of series TO 10
- Exercise period: 20 November 2024 - 4 December 2024.
- Issue size: 32,221,672 warrants of series TO 10, which entitles to subscription of 805,541 shares. If all the warrants are exercised, the Company will receive approximately SEK 14.4 million before issuing costs.
- Forty (40) warrants of series TO 10 will be required to subscribe for one (1) new share in the Company.
- Exercise price: SEK 17.91 per share.
- Last day for trading warrants of series TO 10: 2 December 2024.
- Dilution: If all warrants are exercised the share capital will increase with SEK 3,580,182.228718. If all warrants of series TO 10 are exercised the number of shares will increase with 805,541 shares. The dilution if all warrants of series TO 10 are exercised amounts to approximately 27.7 percent of the number of shares and votes in the Company.
Note that the warrants that are not exercised on 4 December 2024 at the latest or sold no later than on 2 December 2024, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.
How warrants are exercised
Nominee-registered warrants (Custody account) - Subscription and payment by the exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information. This should be done well before 4 December 2024, as different nominees have different processing times.
Directly-registered warrants (Securities account) - No issue report nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.
The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
Additional information, including the TO 10 Subscription Brochure and the application form with payment instructions, will be made available in the Rights Issue 2024 section on ExpreS2ion’s investor website (https://investor.expres2ionbio.com/rights-issue-2024/) at the start of the exercise period. The application form will also be made available on Vator Securities website (www.vatorsecurities.se).
Advisors
Vator Securities act as financial advisor and issuing agent to the Company in connection with the transaction. Advokatfirman Schjødt is the Company's legal advisor in connection with the transaction.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB